acenocoumarol / Generic mfg. - LARVOL DELTA

APIXABAN AND SODIUM THIOSULFATE IN CALCIPHYLAXIS: UNEXPECTED SUCCESSFUL COMBINATION THERAPY (ISN-WCN 2026) - "Radiological investigations (CT-Scan) revealed extensive vascular and soft tissue calcifications, raising suspicion for Calciphylaxis.Download: Download high-res image (283KB)Download: Download full-size imageDownload: Download high-res image (285KB)Download: Download full-size imageDownload: Download high-res image (439KB)Download: Download full-size imageDownload: Download high-res image (347KB)Download: Download full-size imageBased on the disease's pathophysiology and the various contributing factors, the patient underwent multidisciplinary management, including optimization of hemodialysis with a low calcium bath, Extension of hemodialysis sessions thanks to the administration of analgesics such as morphine derivatives. We discontinued the treatments that potentially contributed to the progression of the disease, such as vitamin D, corticosteroid and Acenocoumarol and she underwent dozens hyperbaric oxygen therapy (HBOT)...Early recognition of risk factors and..."

Combination therapy • Calciphylaxis • Immunology • Inflammatory Arthritis • Lupus • Rare Diseases • Systemic Lupus Erythematosus

BEYOND CHADS2-VASC: QUESTIONING SYSTEMIC ANTICOAGULATION IN ADVANCED CHRONIC RENAL DISEASE WITH AURICULAR FIBRILATION (ISN-WCN 2026) - "Even the most recent clinical guidelines recommend individualized use of these scales in this subgroup of patients.Regarding treatment, vitamin K antagonist anticoagulants, such as warfarin or acenocoumarol, have historically been the most widely used drugs...In addition, INR control is especially complex in these patients, with increased risk of overanticoagulation.Direct-acting oral anticoagulants, such as apixaban, edoxaban, rivaroxaban and dabigatran, have demonstrated a better safety profile in certain contexts, with lower bleeding risk than vitamin K antagonist anticoagulants...This scale allows a stratification more adjusted to the renal profile and contributes to reduce unnecessary exposure to anticoagulant treatments with significant bleeding risk.It is necessary to promote a multidisciplinary and individualized approach in the assessment of thromboembolic and bleeding risk in this population, integrating the nephrologist in the therapeutic decision-making..."

Metastases • Atrial Fibrillation • Calciphylaxis • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Rare Diseases • Renal Disease

Treatment Stability of Warfarin and Acenocoumarol in Patients With Mechanical Heart Valves and Atrial Fibrillation: A One-Year Cohort Study. (PubMed, Acta Med Acad) - "Our unadjusted descriptive results suggested that warfarin, compared to acenocoumarol, may provide more stable and therefore safer anticoagulation control in patients with mechanical heart valves and atrial fibrillation. To confirm this, larger prospective clinical studies are needed in patients with mechanical heart valves with or without atrial fibrillation."

Journal • Atrial Fibrillation • Cardiovascular

POOR AWARENESS, LOW DRUG COMPLIANCE, AND SUB-THERAPEUTIC INTERNATIONAL NORMALIZED RATIO LEVELS AMONG RHEUMATIC HEART DISEASE PATIENTS IN NORTHEASTERN INDIA (ACC 2026) - "Most patients used acenocoumarol (92%), while only a few used warfarin (8%) for anticoagulation. Poor awareness, low literacy, low socioeconomic status, and inadequate INR monitoring contribute to poor VKA adherence, inadequate anticoagulation, and increasing morbidity among RHD patients in northeastern India despite guideline recommendations."

Clinical • Compliance • Atrial Fibrillation • Cardiovascular • Heart Failure

Acute STEMI in a Young Adult on Therapeutic Anticoagulation Following Diclofenac Use. (PubMed, J Saudi Heart Assoc) - "This case highlights the serious thrombotic risks associated with NSAID use, even in patients adequately anticoagulated with acenocoumarol. It underscores the necessity of careful NSAID prescribing and demonstrates that therapeutic INR does not offer protection from platelet-driven thrombotic events."

Journal • Acute Coronary Syndrome • Atherosclerosis • Back Pain • Cardiovascular • Musculoskeletal Pain • Myocardial Infarction • Pain

Addressing genetic diversity and health inequities: RELIVAF's proposal for Latin American pharmacogenomic guidelines. (PubMed, Front Pharmacol) - "Three gene-drug pairs were prioritized for initial guideline development: DPYD-fluoropyrimidines, TPMT/NUDT15-thiopurines (paediatric ALL), and CYP2C9/VKORC1-coumarin anticoagulants (e.g., warfarin, acenocoumarol). Selection was based on clinical relevance, allele frequency variability, and potential public health impact. By leveraging regional data and collaborative expertise, RELIVAF aims to deliver actionable, equitable, and context-specific pharmacogenomic guidance, advancing precision medicine in Latin America and serving as a model for other underrepresented regions."

Biomarker • Journal • Review • Pediatrics • CYP2C9 • DPYD • NUDT15

Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series. (PubMed, Transplant Proc) - "Argatroban appears to be an effective and safe alternative anticoagulant for HIT after LVAD implantation, enabling platelet recovery without a significant increase in bleeding or thrombotic events. Differentiating complications attributable to HIT or argatroban from those inherent to LVAD support remains challenging, given the device's intrinsic risks of thrombosis, bleeding, and mortality."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • Thrombosis

The phenprocoumon echo: Elevated INR risk after VKA reversal - A retrospective analysis of phenprocoumon and acenocoumarol in clinical practice in a Dutch teaching hospital. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Retrospective data

Anticoagulation therapeutic ranges and clinical outcomes in patients with a mechanical heart valve treated with vitamin K antagonists. (PubMed, Thromb Haemost) - "A lower therapeutic range does not apparently increase thromboembolic risk in most MHV patients but may be associated with a higher thromboembolic risk in higher risk patients. Lower therapeutic ranges were not associated with lower bleeding risk."

Clinical data • Journal • Cardiovascular

Comparative Outcomes of Apixaban and Acenocoumarol in Advanced Chronic Kidney Disease and Atrial Fibrillation: A Retrospective Observational Study. (PubMed, J Clin Med) - "These findings support apixaban as a safer and more practical anticoagulant option in advanced CKD, consistent with its limited renal clearance and reduced influence on the inflammation-coagulation axis. Further multicenter prospective studies are warranted to validate these real-world results."

Journal • Observational data • Retrospective data • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Inflammation • Nephrology • Renal Disease • Thrombosis

Leukocytoclastic Vasculitis Associated with Coumarin Derivatives: A Case Report. (PubMed, Hosp Pharm) - "Coumarin derivatives, including warfarin and acenocoumarol, are widely used oral anticoagulants that inhibit vitamin K-dependent coagulation factors. Ultimately, transitioning to apixaban led to the complete resolution of symptoms. This case underscores the importance of early recognition of drug-induced vasculitis and highlights the need for individualised anticoagulation strategies in patients with hypersensitivity reactions."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Immunology • Infectious Disease • Vasculitis

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. (PubMed, F1000Res) - "In the xenograft study, tumor size, body weight, and organ weight were significantly attenuated by the test drugs compared with the standard cisplatin. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • KRAS

Time in therapeutic range as predictor of early left-ventricular thrombosis resolution: a retrospective cohort study. (PubMed, Intern Emerg Med) - "The cumulative incidence of early LVT resolution was higher in patients with TTR values ≥ 56% (57.1%; 95% confidence interval-CI 32.8-75.5%) than < 56% (30.3%; 95% CI 15.6-46.4%).The quality of VKAs anticoagulation may be a relevant driver for early LVT resolution. TTR evaluation appears to have a slightly greater accuracy compared to INR variability."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Thrombosis

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hematological Disorders • Thrombosis

Point-of-Care Agitated Saline Contrast Echocardiography in the Diagnosis of Respiratory Failure: A Case of Hepatopulmonary Syndrome With Decompensated Heart Failure. (PubMed, Cureus) - "Past medical history was notable for dilated alcoholic cardiomyopathy, heart failure with reduced ejection fraction (New York Heart Association (NYHA) class II, left ventricle ejection fraction (LVEF) 30%), permanent atrial fibrillation (AF) (on bisoprolol and anticoagulation with acenocoumarol), and a prior mitral valve prosthesis...However, despite high-flow nasal oxygen therapy, subsequent noninvasive ventilation(NIV) (fraction of inspired oxygen (FiO₂) 1.0), and pharmacologic therapy with furosemide resulting in satisfactory diuresis (250 mL/h) and reduced pulmonary congestion on lung ultrasound, oxygenation improved only minimally (PaO₂ up to 40 mmHg), and dyspnea persisted.  Given the presence of cirrhosis with portal hypertension and refractory hypoxemia, and that a workup for HPS had not yet been performed, a bedside agitated-saline contrast echocardiography was performed at the point of care. Microbubbles appeared in the left atrium (LA) and..."

Journal • Addiction (Opioid and Alcohol) • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastroenterology • Heart Failure • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Fetal posterior cerebral artery infarction due to carotid dissection: a case report. (PubMed, J Med Case Rep) - "Fetal posterior cerebral artery and internal carotid artery dissection are frequent separately, but their co-occurrence is exceptional. This report broadens the spectrum of internal carotid artery dissection and discusses the role of fetal posterior cerebral artery in ischemic stroke pathogenesis."

Journal • Cardiovascular • CNS Disorders • Hypertension • Ischemic stroke • Mood Disorders

Time for a Paradigm Shift in Vitamin K Antagonist Reversal - Embracing TGA over INR for Optimal Outcomes? (ASH 2023) - "Participants were pre-treated for 10 days with acenocoumarol to achieve an INR between 2 and 3 (± 10% inclusive)... After 4F-PCC infusion, clotting factors II, VII, IX and X showed dose-dependent increases at 30 min post-dose. Correspondingly, a dose-dependent TGA response was observed; 4F-PCC resulted in restoration to levels measured before anticoagulation with VKA. The degree of INR normalization appeared to be slightly more pronounced in the higher dosed 4F-PCC group."

Thrombosis

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation (ASH 2023) - "Patients in the VKA group received Acenocoumarol. There were no significant differences regarding in all-cause mortality, 18.8% versus 21.5% respectively. CONCLUSIONS Compared to VKA, our findings suggest that low dose of apixaban is a safe and effective alternative in patients with AF and ESKD on hemodialysisis and low dose of apixaban showed predictable pharmacokinetic."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Ischemic stroke • Myocardial Infarction • Nephrology • Renal Disease

Safety of contraception among women using anticoagulant therapy: an updated systematic review. (PubMed, Contraception) - "Women on anticoagulant therapy are at risk for recurrent thrombosis and bleeding, which might be further exacerbated with use of certain contraceptive methods. Additional evidence is needed on safety of concurrent use of anticoagulant medications and contraceptives."

Journal • Review • Cardiovascular • Hematological Disorders • Long-acting Reversible Contraceptives • Venous Thromboembolism

RISK OF ISCHAEMIC STROKE AND INTRACRANIAL BLEEDING WITH DIRECT-ACTING ORAL ANTICOAGULANTS AND WARFARIN COMPARED TO ACENOCOUMAROL (WSC 2025) - "Background and Aims: Most clinical trials and observational studies conducted with direct-acting oral anticoagulants (DOAC: dabigatran, rivaroxaban, apixaban and edoxaban) have used warfarin as the comparator drug. The results suggest that conclusions drawn from studies using warfarin as the reference drug should not be automatically extrapolated to acenocoumarol."

Atrial Fibrillation • Cardiovascular • Ischemic stroke

Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project. (PubMed, J Clin Med) - "Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education."

Journal • Cardiovascular

Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. (PubMed, Int J Clin Pharmacol Ther) - "Renal function, as measured by BSA-adjusted eGFR, is a critical determinant of acenocoumarol dose requirements. These findings support the inclusion of renal function in future acenocoumarol dose calculators and emphasize the importance of individualized dosing strategies."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Insights into the alteration of vaginal microbiota and metabolites in pregnant woman with preterm delivery: prospective cohort study. (PubMed, Front Cell Infect Microbiol) - "In addition, vaginal metabolomics-based LC-Orbitrap-MS/MS revealed that the contents of 2-Piperidone, Melphalan, N-acetylputrescine, Obatoclax, Eurostoside, Pregnanediol 3-O-glucuronide, O-Phospho-L-serine, 1-Kestose and N-arachidonylglycine were significantly decreased in the PrPG group compared with the PrTG group, while Acenocoumarol, Isopyrazam, Pentosidine, hexose, 7-Hydroxymitragynine, PE, Tamoxifen and 1-Deoxynojirimycin contents were significantly increased. These results suggest that specific bacterial species and metabolites may serve as potential biomarkers for preterm birth prediction, and approve the theoretical basis for the intervention of preterm birth."

Journal

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia. (PubMed, Hematol Rep) - "Case Presentation: A 33-year-old woman with congenital thrombophilia (type I protein S deficiency and heterozygous Factor V Leiden mutation) and a history of VTE on long-term anticoagulation with acenocoumarol presented with CML. She exhibited primary resistance to first-line imatinib and poor tolerance with suboptimal response to second-line bosutinib... This case highlights the importance of individualized, multidisciplinary management in CML patients with coexisting thrombophilia. Asciminib, with its favorable cardiovascular safety profile, represents a promising therapeutic option in high-risk patients where other TKIs may be contraindicated due to resistance, intolerance, or thrombotic risk."

Journal • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Venous Thromboembolism • PROS1

Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. (PubMed, J Clin Med) - "Anticoagulants analyzed included warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, betrixaban, and acenocoumarol; antiplatelets included aspirin, clopidogrel, ticagrelor, cilostazol, prasugrel, and dipyridamole. While our findings highlight potential safety signals related to hemorrhage with antithrombotic drug combinations, they remain hypothesis-generating and should not be interpreted as causal associations. Instead, they provide an initial basis for further validation in well-designed clinical cohorts where comorbidities can be adequately accounted for."

Adverse events • Journal • Hematological Disorders